Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of LM-302 plus toripalimab in CLDN18.2-positive advanced gastrointestinal tumors
CTR20231421Phase 2Active
- Sponsor
- LaNova Medicines
- Start
- Jul 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tpx-4589, toripalimab in gastrointestinal neoplasia, sponsored by LaNova Medicines. Started Jul 2023; status: active.
02
Drugs
tpx-4589toripalimab
03
Conditions
gastrointestinal neoplasia
Beyond the preview
Go deeper on CTR20231421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231421.